The curing regimens of HCV: A SWOT analysis

Cornberg, Markus; Manns, Michael P.

doi:10.1177/13596535211072672

Cited by 11 publications

(5 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DAA therapy is overall well tolerated. Usually, two DAAs belonging to different drug classes are combined, and almost any patient can now be successfully treated [ 34 , 35 ]. In line with this, all of the patients were appropriate for DAA therapy according to recent guidelines [ 36 ].…”

Section: Methodsmentioning

confidence: 99%

Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection

et al. 2022

View full text Add to dashboard Cite

Background Hepatitis C virus (HCV) infection is associated with serum lipid abnormalities, which partly normalize following direct-acting antiviral (DAA) therapy. Here, associations of serum triglycerides (TGs) with viral genotype and markers of liver disease severity were evaluated in patients with chronic HCV. Methods The study included the serum of 177 patients with chronic HCV. TGs were quantified by flow injection analysis Fourier transform mass spectrometry. Laboratory values and noninvasive scores for liver fibrosis assessment were determined. The nonparametric Kruskal‒Wallis test, one-way ANOVA, multiple linear regression and Student’s t test were used as appropriate. P values were adjusted for multiple comparisons. Results HCV-infected women had lower serum TGs than men, and thus, a sex-specific analysis was performed. None of the 46 TG species analyzed differed in the serum of female patients with and without liver cirrhosis. In contrast, in the serum of male patients with liver cirrhosis, TGs with 53, 56 and 58 carbon atoms and three to eight double bonds were diminished. These polyunsaturated TGs were also low in males with a high fibrosis-4 score. TGs with 7 or 8 double bonds negatively correlated with the model of end-stage liver disease score in males. In addition, TGs with 49, 51 and 53 carbon atoms were reduced in male patients infected with genotype 3a in comparison to genotype 1a. TGs with 56 carbon atoms were lower in genotype 3a-infected males than in genotype 1b-infected males. TGs did not differ in females by genotype. Genotype 3-related changes disappeared at the end of therapy with DAAs. Overall, the levels of serum TGs did not change during DAA therapy in either sex. Consequently, the serum TGs of males with liver cirrhosis were lower than those of males without cirrhosis at the end of therapy. Such a difference was not apparent in females. Conclusions The decline in TGs observed only in male patients with liver cirrhosis and male patients infected with genotype 3 illustrates sex-specific changes in lipid metabolism in chronic HCV.

show abstract

Section: Methodsmentioning

confidence: 99%

Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Its pharmacokinetics support once-daily dosing, offering convenience for patients. Clinical trials have validated its efficacy and safety, positioning daclatasvir as a pivotal option for patients with HCV genotype 3 infection (6). Another significant advancement in HCV treatment is sofosbuvir, an oral nucleotide analogue effective against all HCV genotypes.…”

Section: Introductionmentioning

confidence: 99%

Effect of Antiviral Drug on Viral Load Patients Infected with Hepatitis C Virus Genotype 3

Ali,

Parkash,

Bhatti

et al. 2024

JHRR

View full text Add to dashboard Cite

Background: Hepatitis C Virus (HCV) genotype 3 is recognized for its rapid progression towards liver fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma, particularly in regions with high prevalence rates like Pakistan. Despite advances in treatment, understanding the efficacy and outcomes of direct-acting antiviral (DAA) therapy in this specific genotype remains crucial for optimizing clinical management and public health strategies. Objective: This study aims to evaluate the efficacy and safety of daclatasvir and sofosbuvir combination therapy in patients with HCV genotype 3 infection, focusing on sustained virologic response (SVR), viral load reduction, and treatment-related adverse events. Methods: A single-group, pretest-posttest design was utilized, involving 130 participants diagnosed with HCV genotype 3. Patients received a 12-week regimen of daclatasvir (60mg daily) and sofosbuvir (400mg daily). The study conducted thorough pre-treatment and post-treatment assessments, including ELISA for HCV antibodies, PCR for viral load determination, and genotyping. Statistical analyses were performed using SPSS version 25, with significance set at p<0.05. Results: Of the 130 participants, 93% achieved SVR at 12 weeks post-treatment. The pre-treatment viral load ranged from 78,200 to 120,900,000 IU/mL, significantly decreasing post-treatment across the cohort. Genotype analysis confirmed HCV genotype 3 in 85.71% of cases. Treatment was well-tolerated, with no serious adverse events reported. Conclusion: The combination therapy of daclatasvir and sofosbuvir was highly effective and safe in treating patients with HCV genotype 3 infection, demonstrating a high rate of SVR and a significant reduction in viral load without severe adverse events. These findings support the use of this regimen as a viable treatment option for this challenging HCV genotype.

show abstract

“…While patients achieving SVR experience improvements in extrahepatic manifestations and a reduced risk of cirrhosis and HCC, subsequent complications and the risk of HCC are not entirely eliminated in all patients 3 6 . Especially in patients with cirrhosis and other risk factors, the risk of HCC remains high 7 8 . One possible reason for this could be biological imprints of HCV infection that are still present after SVR 9 10 .…”

Section: Introductionmentioning

confidence: 99%

The impact of cirrhosis on the inflammatory milieu before and long-term after hepatitis C virus elimination by direct-acting antiviral therapy

Witte,

Oltmanns,

Tauwaldt

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background and AimsChronic hepatitis C virus (HCV) infection can lead to cirrhosis, development of hepatocellular carcinoma (HCC) and several extrahepatic manifestations. A sustained virological response (SVR) is achieved with direct-acting antivirals (DAA) in over 95% of the patients, but sequelae do not improve in all patients, suggesting permanent biological alterations induced by HCV infection. Therefore, we investigated the influence of chronic HCV infection, viral elimination and cirrhosis on inflammatory immune mediators.Approach and ResultsIn 102 chronic HCV patients, 46 with and 56 without cirrhosis, 92 soluble immune mediators (SIM) were measured in plasma samples at therapy start, end of treatment and long-term follow-up (median 96 weeks). 39 HBsAg positive persons with HBeAg negative infection served as controls.At baseline, 42 SIM were altered in chronic HCV patients (adj.p <0.05). Notably, patients with cirrhosis displayed a higher frequency and severity of alterations. At long-term follow-up, the SIM profile of the non-cirrhotic patients recovered to the level of the control group, while 41 SIM remained altered in cirrhotic patients. 33 of these SIM correlated with elastography, among them SIM linked to carcinogenesis as e.g. HGF, IL8 and IL6 (KEGG Pathways hsa05202, hsa05200).ConclusionsHCV-related changes in the inflammatory milieu can persist even after HCV elimination, specifically in cirrhotic patients. These changes are closely associated with liver damage and carcinogenesis. Our findings underscore the need for HCV elimination before extensive liver injury occurs and suggest further investigation of the relationship between persistent inflammatory milieu changes and long-term sequelae after HCV elimination.Graphical Abstract

show abstract

The curing regimens of HCV: A SWOT analysis

Cited by 11 publications

References 96 publications

Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection

Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection

Effect of Antiviral Drug on Viral Load Patients Infected with Hepatitis C Virus Genotype 3

The impact of cirrhosis on the inflammatory milieu before and long-term after hepatitis C virus elimination by direct-acting antiviral therapy

Contact Info

Product

Resources

About